SBIR Phase I: Sensitive, Rapid Heterogeneous Immunoassays Based on Surface Enhanced Raman Scattering and Gold Nanoparticle Labels

SBIR 第一阶段：基于表面增强拉曼散射和金纳米颗粒标记的灵敏、快速异质免疫测定

• 批准号: 0839773
• 负责人: Christian Schoen
• 金额: --
• 依托单位: Concurrent Analytical, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0839773&HistoricalAwards=false
• 关键词: SBIR; Phase; Sensitive; Rapid; Heterogeneous

This Small Business Innovation Research (SBIR) Phase I project develops a diagnostic platform for herpes viruses by combining gold nanoparticle labels, high-speed fluid handling, and sandwich-based heterogeneous immunoassays with advances in surface enhanced Raman scattering (SERS). Herpes has reached near epidemic levels in the United States and other countries. Current diagnostic approaches severely limit broad level testing of the causative agents of this disease, herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2). This application reflects the increase in market need for a high-speed, low-cost testing platform capable of quantifying HSV levels critical to diagnosis (tens to hundreds of viruses per milliliter of sample). The broader impacts of this research are demonstrated by the urgent need for reliable techniques that can be deployed as rapid, low-cost analysis methods ranging from point-of-care (POC) diagnostics in the doctor?s office or hospital, to laboratory testing. Presently more than 50 million Americans have genital herpes, with another 1% of the U.S. population predicted to become infected annually. A 1999 survey showed ~20% of pregnant women tested positively for HSV-2 antibodies. If economic and rapid POC testing were available as a litmus test for HSV-2 in maternity wards, more informed decisions for herpes necessitated cesarean deliveries could be made, thereby protecting the immune-compromised neonates. A technique capable of quantifying HSV at the noted levels would also find a niche in the researcher?s laboratory in evaluating the antiviral effectiveness of candidate vaccines, as well as by pathologists in defining infective pathogen thresholds.

该小型企业创新研究（SBIR）第一阶段项目开发了一个疱疹病毒的诊断平台，结合了金纳米颗粒标记，高速流体处理和基于荧光素的异质性免疫测定与表面增强拉曼散射（Sers）的进步。疱疹在美国和其他国家已达到接近流行的水平。目前的诊断方法严重限制了对这种疾病的病原体，1型和2型单纯疱疹病毒（HSV-1和HSV-2）的广泛水平测试。该应用反映了市场对高速、低成本测试平台的需求增加，该平台能够量化对诊断至关重要的HSV水平（每毫升样本中有数十至数百个病毒）。这项研究的更广泛的影响表明，迫切需要可靠的技术，可以部署为快速，低成本的分析方法，从护理点（POC）诊断在医生？的办公室或医院，实验室检测。目前，超过5000万美国人患有生殖器疱疹，预计每年另有1%的美国人口感染。1999年的一项调查显示，约20%的孕妇HSV-2抗体检测呈阳性。如果经济和快速的POC检测可作为产科病房HSV-2的试金石测试，则可以对需要剖腹产的疱疹做出更明智的决定，从而保护免疫受损的新生儿。一种能够在上述水平上量化HSV的技术也会在研究人员中找到一席之地？实验室在评估候选疫苗的抗病毒效果，以及由病理学家在定义感染性病原体阈值。